Patent ductus arteriosus medical therapy in term and older children: Difference between revisions
Jump to navigation
Jump to search
(/* ACC/AHA recommendations for medical therapy in patients with patent ductus arteriosus(DONOT EDIT){{cite journal| author=Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA et al.| title=ACC/AHA 2008 guidelines for the manageme...) |
|||
| (8 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Patent ductus arteriosus}} | {{Patent ductus arteriosus}} | ||
{{CMG}}; '''Associate Editor-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com], {{CZ}}; '''Assistant Editor-In-Chief:''' [[Kristin Feeney|Kristin Feeney, B.S.]] [mailto:kfeeney@elon.edu] | {{CMG}}; '''Associate Editor-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com], {{CZ}}; '''Assistant Editor-In-Chief:''' [[Kristin Feeney|Kristin Feeney, B.S.]] [mailto:kfeeney@elon.edu] | ||
==Overview== | ==Overview== | ||
In term infants and older patients, the | In term [[Infant|infants]] and older patients, the [[prostaglandin]] E2 inhibitors ([[indomethacin]] and [[ibuprofen]]) have not shown to be effective. This is so because the ductus in [[premature]] baby is different [[histological]] from in older patients. As a result, pharmacologic therapy is only used routinely in [[preterm]] infants. | ||
==2008 ACC/AHA Guidelines for the Management of Adults | ==2008 ACC/AHA Guidelines for the Management of Adults with Congenital Heart Disease (DO NOT EDIT)<ref name="pmid19038677">{{cite journal| author=Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA et al.| title=ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. | journal=J Am Coll Cardiol | year= 2008 | volume= 52 | issue= 23 | pages= e1-121 | pmid=19038677 | doi=10.1016/j.jacc.2008.10.001 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19038677 }} </ref> == | ||
=== Recommendations for | === Recommendations for Medical Therapy (DO NOT EDIT)<ref name="pmid19038677">{{cite journal| author=Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA et al.| title=ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. | journal=J Am Coll Cardiol | year= 2008 | volume= 52 | issue= 23 | pages= e1-121 | pmid=19038677 | doi=10.1016/j.jacc.2008.10.001 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19038677 }} </ref> === | ||
{| class="wikitable" | {| class="wikitable" | ||
|- | |- | ||
| Line 19: | Line 20: | ||
|- | |- | ||
| bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Endocarditis prophylaxis is not recommended for those with a repaired PDA without residual shunt. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | | bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' [[Endocarditis prophylaxis]] is not recommended for those with a repaired PDA without residual [[shunt]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | ||
|} | |} | ||
| Line 26: | Line 27: | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 18:20, 13 March 2020
|
Patent Ductus Arteriosus Microchapters |
|
Differentiating Patent Ductus Arteriosus from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Medical Therapy |
|
Case Studies |
|
Patent ductus arteriosus medical therapy in term and older children On the Web |
|
American Roentgen Ray Society Images of Patent ductus arteriosus medical therapy in term and older children |
|
FDA on Patent ductus arteriosus medical therapy in term and older children |
|
CDC on Patent ductus arteriosus medical therapy in term and older children |
|
Patent ductus arteriosus medical therapy in term and older children in the news |
|
Blogs on Patent ductus arteriosus medical therapy in term and older children |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Priyamvada Singh, M.B.B.S. [2], Cafer Zorkun, M.D., Ph.D. [3]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [4]
Overview
In term infants and older patients, the prostaglandin E2 inhibitors (indomethacin and ibuprofen) have not shown to be effective. This is so because the ductus in premature baby is different histological from in older patients. As a result, pharmacologic therapy is only used routinely in preterm infants.
2008 ACC/AHA Guidelines for the Management of Adults with Congenital Heart Disease (DO NOT EDIT)[1]
Recommendations for Medical Therapy (DO NOT EDIT)[1]
| Class I |
| "1. Routine follow-up is recommended for patients with a small PDA without evidence of left-sided heart volume overload. Follow-up is recommended every 3 to 5 years for patients with a small PDA without evidence of left-heart volume overload.(Level of Evidence: C) " |
| Class III (Harm) |
| "1. Endocarditis prophylaxis is not recommended for those with a repaired PDA without residual shunt. (Level of Evidence: C) " |
References
- ↑ 1.0 1.1 Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA; et al. (2008). "ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". J Am Coll Cardiol. 52 (23): e1–121. doi:10.1016/j.jacc.2008.10.001. PMID 19038677.